These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21472138)

  • 1. Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
    Dean EJ; Cummings J; Roulston A; Berger M; Ranson M; Blackhall F; Dive C
    Neoplasia; 2011 Apr; 13(4):339-47. PubMed ID: 21472138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
    Chiappori AA; Schreeder MT; Moezi MM; Stephenson JJ; Blakely J; Salgia R; Chu QS; Ross HJ; Subramaniam DS; Schnyder J; Berger MS
    Br J Cancer; 2012 Feb; 106(5):839-45. PubMed ID: 22333598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
    Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
    Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.
    Micha D; Cummings J; Shoemaker A; Elmore S; Foster K; Greaves M; Ward T; Rosenberg S; Dive C; Simpson K
    Clin Cancer Res; 2008 Nov; 14(22):7304-10. PubMed ID: 19010845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
    Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
    Hou JM; Greystoke A; Lancashire L; Cummings J; Ward T; Board R; Amir E; Hughes S; Krebs M; Hughes A; Ranson M; Lorigan P; Dive C; Blackhall FH
    Am J Pathol; 2009 Aug; 175(2):808-16. PubMed ID: 19628770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
    de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
    Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
    Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
    Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
    Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
    Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
    Qiu Z; Lin A; Li K; Lin W; Wang Q; Wei T; Zhu W; Luo P; Zhang J
    Drug Des Devel Ther; 2019; 13():2021-2041. PubMed ID: 31417239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
    Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
    Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A randomized controlled study of chemotherapy: etoposide combined with oxaliplatin or cisplatin regimens in the treatment of extensive-stage small cell lung cancer in elderly patients].
    Pu D; Hou M; Li Z; Zeng X
    Zhongguo Fei Ai Za Zhi; 2013 Jan; 16(1):20-4. PubMed ID: 23327869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients.
    Faivre C; El Cheikh R; Barbolosi D; Barlesi F
    Br J Cancer; 2017 Jan; 116(3):344-348. PubMed ID: 28081545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
    Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
    Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.